Abeona Therapeutics Inc (NASDAQ: ABEO) kicked off on Friday, down -5.62% from the previous trading day, before settling in for the closing price of $4.45. Over the past 52 weeks, ABEO has traded in a range of $2.83-$9.01.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -15.07%. While this was happening, its average annual earnings per share was recorded 15.55%. With a float of $37.50 million, this company’s outstanding shares have now reached $39.64 million.
Let’s determine the extent of company efficiency that accounts for 84 employees.
Abeona Therapeutics Inc (ABEO) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Abeona Therapeutics Inc is 5.40%, while institutional ownership is 42.27%. The most recent insider transaction that took place on Apr 26 ’24, was worth 24,764. In this transaction Director of this company bought 7,550 shares at a rate of $3.28, taking the stock ownership to the 78,323 shares. Before that another transaction happened on Apr 25 ’24, when Company’s Chief Executive Officer bought 10,000 for $3.20, making the entire transaction worth $32,000. This insider now owns 538,260 shares in total.
Abeona Therapeutics Inc (ABEO) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 12/31/2023, the organization reported -0.54 earnings per share (EPS), higher than consensus estimate (set at -0.58) by 0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.53 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 15.55% per share during the next fiscal year.
Abeona Therapeutics Inc (NASDAQ: ABEO) Trading Performance Indicators
Take a look at Abeona Therapeutics Inc’s (ABEO) current performance indicators. Last quarter, stock had a quick ratio of 4.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 47.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.59, a number that is poised to hit -0.51 in the next quarter and is forecasted to reach -1.90 in one year’s time.
Technical Analysis of Abeona Therapeutics Inc (ABEO)
Looking closely at Abeona Therapeutics Inc (NASDAQ: ABEO), its last 5-days average volume was 1.08 million, which is a jump from its year-to-date volume of 0.55 million. As of the previous 9 days, the stock’s Stochastic %D was 56.80%. Additionally, its Average True Range was 0.60.
During the past 100 days, Abeona Therapeutics Inc’s (ABEO) raw stochastic average was set at 19.30%, which indicates a significant decrease from 55.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 338.66% in the past 14 days, which was higher than the 149.75% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.68, while its 200-day Moving Average is $5.07. However, in the short run, Abeona Therapeutics Inc’s stock first resistance to watch stands at $4.44. Second resistance stands at $4.67. The third major resistance level sits at $4.85. If the price goes on to break the first support level at $4.03, it is likely to go to the next support level at $3.85. Now, if the price goes above the second support level, the third support stands at $3.62.
Abeona Therapeutics Inc (NASDAQ: ABEO) Key Stats
The company with the Market Capitalisation of 166.49 million has total of 27,355K Shares Outstanding. Its annual sales at the moment are 3,500 K in contrast with the sum of -54,190 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -11,840 K.
